Cargando…
The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview
Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortality rates among all cancer types. Its delayed diagnosis precludes curative resection, thus most of the current therapies against PDAC are based on chemo- and radiotherapy. Unfortunately, these strategies are insufficient to improve...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Anti-Cancer Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936232/ https://www.ncbi.nlm.nih.gov/pubmed/31908888 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0252 |
_version_ | 1783483704383897600 |
---|---|
author | Quiñonero, Francisco Mesas, Cristina Doello, Kevin Cabeza, Laura Perazzoli, Gloria Jimenez-Luna, Cristina Rama, Ana Rosa Melguizo, Consolación Prados, Jose |
author_facet | Quiñonero, Francisco Mesas, Cristina Doello, Kevin Cabeza, Laura Perazzoli, Gloria Jimenez-Luna, Cristina Rama, Ana Rosa Melguizo, Consolación Prados, Jose |
author_sort | Quiñonero, Francisco |
collection | PubMed |
description | Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortality rates among all cancer types. Its delayed diagnosis precludes curative resection, thus most of the current therapies against PDAC are based on chemo- and radiotherapy. Unfortunately, these strategies are insufficient to improve its poor prognosis. Despite the advances made in chemotherapy (e.g. nab-paclitaxel and gemcitabine), many patients with PDAC are unable to benefit from them due to the rapid development of drug resistance. Currently, more than 165 genes have been found to be implicated in drug resistance of pancreatic tumors, including different integrins, mucins, NF-κB, RAS and CXCR4. Moreover, drug resistance in PDAC is thought to be mediated by the modulation of miRNAs (e.g. miRNA-21, miRNA-145 and miRNA-155), which regulate genes that participate in cell proliferation, invasion and metastasis. Finally, cancer stem cells are intimately related to drug resistance in PDAC due to their ability to overexpress ABC genes -involved in drug transport-, and enzymes such as aldehyde dehydrogenases -implicated in cellular drug metabolism- and poly (ADP-ribose) polymerases -involved in drug-induced DNA damage repair. Understanding the mechanisms involved in drug resistance will contribute to the development of efficient therapeutic strategies and to improve the prognosis of patients with PDAC. |
format | Online Article Text |
id | pubmed-6936232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Chinese Anti-Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-69362322020-01-06 The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview Quiñonero, Francisco Mesas, Cristina Doello, Kevin Cabeza, Laura Perazzoli, Gloria Jimenez-Luna, Cristina Rama, Ana Rosa Melguizo, Consolación Prados, Jose Cancer Biol Med Review Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortality rates among all cancer types. Its delayed diagnosis precludes curative resection, thus most of the current therapies against PDAC are based on chemo- and radiotherapy. Unfortunately, these strategies are insufficient to improve its poor prognosis. Despite the advances made in chemotherapy (e.g. nab-paclitaxel and gemcitabine), many patients with PDAC are unable to benefit from them due to the rapid development of drug resistance. Currently, more than 165 genes have been found to be implicated in drug resistance of pancreatic tumors, including different integrins, mucins, NF-κB, RAS and CXCR4. Moreover, drug resistance in PDAC is thought to be mediated by the modulation of miRNAs (e.g. miRNA-21, miRNA-145 and miRNA-155), which regulate genes that participate in cell proliferation, invasion and metastasis. Finally, cancer stem cells are intimately related to drug resistance in PDAC due to their ability to overexpress ABC genes -involved in drug transport-, and enzymes such as aldehyde dehydrogenases -implicated in cellular drug metabolism- and poly (ADP-ribose) polymerases -involved in drug-induced DNA damage repair. Understanding the mechanisms involved in drug resistance will contribute to the development of efficient therapeutic strategies and to improve the prognosis of patients with PDAC. Chinese Anti-Cancer Association 2019-11 /pmc/articles/PMC6936232/ /pubmed/31908888 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0252 Text en Copyright 2019 Cancer Biology & Medicine http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Review Quiñonero, Francisco Mesas, Cristina Doello, Kevin Cabeza, Laura Perazzoli, Gloria Jimenez-Luna, Cristina Rama, Ana Rosa Melguizo, Consolación Prados, Jose The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview |
title | The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview |
title_full | The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview |
title_fullStr | The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview |
title_full_unstemmed | The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview |
title_short | The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview |
title_sort | challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936232/ https://www.ncbi.nlm.nih.gov/pubmed/31908888 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0252 |
work_keys_str_mv | AT quinonerofrancisco thechallengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT mesascristina thechallengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT doellokevin thechallengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT cabezalaura thechallengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT perazzoligloria thechallengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT jimenezlunacristina thechallengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT ramaanarosa thechallengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT melguizoconsolacion thechallengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT pradosjose thechallengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT quinonerofrancisco challengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT mesascristina challengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT doellokevin challengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT cabezalaura challengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT perazzoligloria challengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT jimenezlunacristina challengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT ramaanarosa challengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT melguizoconsolacion challengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview AT pradosjose challengeofdrugresistanceinpancreaticductaladenocarcinomaacurrentoverview |